Low Dose Desferrioxamine Can Improve Erythropoiesis in Iron-Overload Hemodialysis Patients Without Side Effects

References

• Bell J D, Kingcaid W R, Morgan R G, Bunce H, Alperin J B, Sarles H E, et al. Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis. Kidney Int 1980; 17: 237–241
   PubMed Web of Science ®Google Scholar
• Hakim R M, Stivelman J C, Schulman G, Fosburg M, Wolfe L, Imber M J., et al. Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis 1987; 4: 293–299
   Google Scholar
• Eschbach J W, Egrie J C, Downing M R., Browne J K, Adamson J W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Eng J Med 1987; 316: 73–78
   PubMed Web of Science ®Google Scholar
• Malluche H H, Smith A J, Abreo K, Faugere M C. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure. N Eng J Med 1984; 311: 140–144
   PubMed Web of Science ®Google Scholar
• Baker L RI, Brozovic B B, Cattell W R, Ackrill P, McAlister J, Nimmon C. Hemosiderosis in a patient on regular hemodialysis treatment by desferrioxamine. Clin Nephrol 1976; 6: 326–328
   PubMedGoogle Scholar
• Simon P. Detoxification in hemosiderosis. Blood Purifi 1985; 3: 75–88
   PubMedGoogle Scholar
• Vreugdenhil G, Smeets M, Fedders R A, van Eijk H G. Iron chelators may enhance erythropoiesis by increasing iron delivery to hematopoietic tissue and erythropoietin response in iron-loading anemia. Acta Haematol 1993; 89: 57–60
   PubMed Web of Science ®Google Scholar
• Roger S D, Stewart J H, Harris D CH. Desferrioxamine enhances the hemopoietic response to erythropoietin, but adverse events are common. Nephron 1991; 58: 33–36
   PubMed Web of Science ®Google Scholar
• Serna E J, Praga M, Sanz F G, Rodicio J L, Ruilope L M, Alcazar J M. Improvement in the erythropoiesis of chrome hemodialysis patients with desferrioxamine. Lancet 1988; May: 1009–1011
   Google Scholar
• Praga M, Andres A, Serna J, Ruilope L M, Nieto J, Estenoz J, et al. Improvement of anemia with desferrioxamine in hemodialysis patients. Nephrol Dial Transplant 1987; 2: 243–247
   PubMedGoogle Scholar
• Pitts T O, Barbour G. Hemosiderosis secondary to chronic parenternal iron therapy in maintenance hemodialysis patients. Nephron 1978; 22: 316–322
   PubMed Web of Science ®Google Scholar
• Gokal R, Millard P R, Weatherall D J, Callender S TE, Ledingham J GG, Oliver D O. Iron metabolism in hemodialysis patients. Q J Med 1979; 191: 369–391
   Google Scholar
• Hussein S, Prieto J, Oshea M, Hoffbrand A V, Baillod R A, Moorhead J F. Serum ferritin assay and iron status in chronic renal failure and hemodialysis. Brit J Med 1975; 1: 546–548
   PubMed Web of Science ®Google Scholar
• Van de Vyver F, Vanheule A A, Majelyne W M, D'Hhaese P, Blocky P P, Bekaert A B, et al. Serum ferritin as a guide for iron stores in chronic hemodialysis patients. Kidney Int 1984; 26: 451–458
   PubMed Web of Science ®Google Scholar
• Marchi S D, Cecchin E. Hepatic computed tomography for monitoring the iron status of hemodialysis patients with hemosiderosis treated with recombinant human erythropoietin. Clin Sci 1991; 81: 113–121
   Web of Science ®Google Scholar
• Cecchin E, Marchi S D, Querin F, Marin M G, Fiorentino R, Tesio F. Efficacy of hepatic computed tomography to detect iron overload in chronic hemodialysis. Kidney Int 1990; 37: 943–950
   PubMed Web of Science ®Google Scholar
• Worwood M. Ferrttin. Blood Rev 1990; 4: 259–269
   PubMed Web of Science ®Google Scholar
• Fishbane S, Maesaka J K. Iron management in end-stage renal disease. Am J Kidney Dis 1997; 3: 319–333
   Google Scholar
• Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem J L, Tielemans C. Resistance to erythropoietin in iron-overloaded hemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 1995; 10: 44–47
   PubMed Web of Science ®Google Scholar
• Birgegard J G, Danielson B G, Wikstrom B. Treatment of erythropoietin-resistant anemia with desferrioxamine in patients on hemofiltration. Eur J Haematol 1995; 55: 73–77
   PubMed Web of Science ®Google Scholar
• Eschbach J W, Downing M R, Egrie J C, Browne J K, Adamson J W. USA muhicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 160–165
   PubMedGoogle Scholar
• McCarthy J T, Johnson W J, Nixon D E, Jenson B M, Moyer T P. Transfusional iron overload in patients undergoing dialysis: Treatment with erythropoietin and phlebotomy. J Lab Chin Med 1989; 114: 193–199
   PubMed Web of Science ®Google Scholar
• Lazarus J M, Hakim R M, RN L N. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients. Am J Kidney Dis 1990; 2: 101–108
   Google Scholar
• Bia M J, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, et al. Aluminum induced anemia pathogenesis and treatment in patients on chronic hemodialysis. kidney Int 1989; 36: 852–859
   PubMed Web of Science ®Google Scholar
• Cannata Andia J B. Aluminum toxicity its relationship with bone and iron metabolism. Nephrol Dial Transplant 1996; 11: 69–71
   PubMed Web of Science ®Google Scholar
• El-Reshaid K, Johny K V, Hakim A, Karnel H, Sebeta A, Hourani H, et al. Erythropoietin treatment in hemodialysis patients with iron overload. Acta Haematol 1994; 91: 130–135
   PubMed Web of Science ®Google Scholar
• Vreugdenhil G, Feelder A, Coppens J W, de Leeuw W. Possible mechanisms underlying potentiating effects of iron ehelators in hematopoietic response to erythropoietin. Nephron 1992; 61: 475–476
   PubMed Web of Science ®Google Scholar
• D'Haese P C, Couttenye M M, De Broc M E. Diagnosis and treatment of aluminum bone disease. Nephrol Dial Transplant 1996; 11: 74–79
   PubMed Web of Science ®Google Scholar
• Stivelman J, Sehulman G, Fosburg M, Lazarus J M, Hakim R M. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients. Kidney Int 1989; 36: 1125–1132
   PubMed Web of Science ®Google Scholar